Trial Profile
A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Daprodustat (Primary) ; Recombinant erythropoietin
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Nov 2014 New trial record